Literature DB >> 26165583

Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer.

Zachary S Zumsteg1, Daniel E Spratt1, Paul B Romesser1, Xin Pei1, Zhigang Zhang1, Marisa Kollmeier1, Sean McBride1, Yoshiya Yamada1, Michael J Zelefsky2.   

Abstract

PURPOSE: We provide a comprehensive analysis of anatomical patterns of recurrence following external beam radiotherapy in patients with localized prostate cancer. <br> MATERIALS AND METHODS: This retrospective analysis included 2,694 patients with localized prostate cancer who received definitive, dose escalated external beam radiotherapy from 1991 to 2008. First recurrence sites were defined as initial sites of clinically detected recurrence and any subsequent clinically detected recurrence within 3 months. Anatomical recurrence patterns were classified as local (prostate/seminal vesicles only), lymphotropic (lymph nodes only) and osteotropic (bones only) in patients with disease confined only to these respective sites for at least 2 years from the initial clinically detected recurrence. <br> RESULTS: Prostate was the most common first recurrence site in the low, intermediate and high risk groups with an 8-year cumulative incidence of 3.5%, 9.8% and 14.6%, respectively. The 8-year risk of isolated pelvic lymph node relapse as the first recurrence site was 0%, 1.0% and 3.3%, respectively. In the 474 patients with clinically detected recurrence the most common first recurrence site was local in 55.3%, bone in 33.5%, pelvic lymph nodes in 21.3% and abdominal lymph nodes in 9.1%. Patients showed unique relapse distributions, including a pattern that was local in 41.6%, lymphotropic in 9.7%, osteotropic in 20.3% and multiorgan/visceral in 28.5%. Anatomical recurrence pattern was the strongest predictor of prostate cancer specific mortality on multivariate analysis of patients with clinically detected recurrence. <br> CONCLUSIONS: The most common first recurrence site after dose escalated external beam radiotherapy for prostate cancer is in the prostate and seminal vesicles in all risk groups. In contrast, patients treated without elective pelvic lymph node irradiation are at relatively low risk for isolated pelvic lymph node relapse. Recurrence patterns revealed a tropism for specific anatomical distributions with divergent prognoses, suggesting underlying biological differences among tumors.
Copyright © 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  lymph nodes; prostatic neoplasms; radiotherapy; recurrence; treatment failure

Mesh:

Substances:

Year:  2015        PMID: 26165583      PMCID: PMC5003416          DOI: 10.1016/j.juro.2015.06.100

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  26 in total

1.  Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer despite two negative randomized trials.

Authors:  Paul L Nguyen; Anthony V D'Amico
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

2.  NCCN clinical practice guidelines in oncology: prostate cancer.

Authors:  James Mohler; Robert R Bahnson; Barry Boston; J Erik Busby; Anthony D'Amico; James A Eastham; Charles A Enke; Daniel George; Eric Mark Horwitz; Robert P Huben; Philip Kantoff; Mark Kawachi; Michael Kuettel; Paul H Lange; Gary Macvicar; Elizabeth R Plimack; Julio M Pow-Sang; Mack Roach; Eric Rohren; Bruce J Roth; Dennis C Shrieve; Matthew R Smith; Sandy Srinivas; Przemyslaw Twardowski; Patrick C Walsh
Journal:  J Natl Compr Canc Netw       Date:  2010-02       Impact factor: 11.908

3.  Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.

Authors:  James W Denham; Allison Steigler; David S Lamb; David Joseph; Sandra Turner; John Matthews; Chris Atkinson; John North; David Christie; Nigel A Spry; Keen-Hun Tai; Chris Wynne; Catherine D'Este
Journal:  Lancet Oncol       Date:  2011-05       Impact factor: 41.316

4.  Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix.

Authors:  Michael J Zelefsky; James A Eastham; Angel M Cronin; Zvi Fuks; Zhigang Zhang; Yoshiya Yamada; Andrew Vickers; Peter T Scardino
Journal:  J Clin Oncol       Date:  2010-02-16       Impact factor: 44.544

5.  The effect of salvage therapy on survival in a longitudinal study with treatment by indication.

Authors:  Edward H Kennedy; Jeremy M G Taylor; Douglas E Schaubel; Scott Williams
Journal:  Stat Med       Date:  2010-11-10       Impact factor: 2.373

6.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

Authors:  Anders Widmark; Olbjørn Klepp; Arne Solberg; Jan-Erik Damber; Anders Angelsen; Per Fransson; Jo-Asmund Lund; Ilker Tasdemir; Morten Hoyer; Fredrik Wiklund; Sophie D Fosså
Journal:  Lancet       Date:  2008-12-16       Impact factor: 79.321

7.  Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.

Authors:  Anthony V D'Amico; Ming-Hui Chen; Andrew A Renshaw; Marian Loffredo; Philip W Kantoff
Journal:  JAMA       Date:  2008-01-23       Impact factor: 56.272

8.  Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.

Authors:  Mack Roach; Kyounghwa Bae; Joycelyn Speight; Harvey B Wolkov; Phillip Rubin; R Jeffrey Lee; Colleen Lawton; Richard Valicenti; David Grignon; Miljenko V Pilepich
Journal:  J Clin Oncol       Date:  2008-01-02       Impact factor: 44.544

9.  Radical prostatectomy or watchful waiting in early prostate cancer.

Authors:  Anna Bill-Axelson; Lars Holmberg; Hans Garmo; Jennifer R Rider; Kimmo Taari; Christer Busch; Stig Nordling; Michael Häggman; Swen-Olof Andersson; Anders Spångberg; Ove Andrén; Juni Palmgren; Gunnar Steineck; Hans-Olov Adami; Jan-Erik Johansson
Journal:  N Engl J Med       Date:  2014-03-06       Impact factor: 91.245

10.  Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.

Authors:  Padraig Warde; Malcolm Mason; Keyue Ding; Peter Kirkbride; Michael Brundage; Richard Cowan; Mary Gospodarowicz; Karen Sanders; Edmund Kostashuk; Greg Swanson; Jim Barber; Andrea Hiltz; Mahesh K B Parmar; Jinka Sathya; John Anderson; Charles Hayter; John Hetherington; Matthew R Sydes; Wendy Parulekar
Journal:  Lancet       Date:  2011-11-02       Impact factor: 79.321

View more
  31 in total

1.  Favorable long-term toxicity for salvage low-dose rate prostate brachytherapy for recurrent prostate cancer after external beam radiotherapy from a phase II prospective trial (NRG Oncology/RTOG 0526).

Authors:  Randall J Brenneman; Edward Soffen; Hiram A Gay; Peter F Orio; John P Christodouleas; John C Baumann; Brian C Baumann
Journal:  Transl Androl Urol       Date:  2019-07

Review 2.  The role of MRI for detection and staging of radio- and focal therapy-recurrent prostate cancer.

Authors:  Henk van der Poel; Nikos Grivas; Pim van Leeuwen; Stijn Heijmink; Ivo Schoots
Journal:  World J Urol       Date:  2019-02-20       Impact factor: 4.226

3.  Radiomics analysis of 18F-Choline PET/CT in the prediction of disease outcome in high-risk prostate cancer: an explorative study on machine learning feature classification in 94 patients.

Authors:  Pierpaolo Alongi; Alessandro Stefano; Albert Comelli; Riccardo Laudicella; Salvatore Scalisi; Giuseppe Arnone; Stefano Barone; Massimiliano Spada; Pierpaolo Purpura; Tommaso Vincenzo Bartolotta; Massimo Midiri; Roberto Lagalla; Giorgio Russo
Journal:  Eur Radiol       Date:  2021-01-14       Impact factor: 5.315

Review 4.  Prostate MR Imaging for Posttreatment Evaluation and Recurrence.

Authors:  Sonia Gaur; Baris Turkbey
Journal:  Radiol Clin North Am       Date:  2017-11-27       Impact factor: 2.303

Review 5.  PET imaging of recurrent and metastatic prostate cancer with novel tracers.

Authors:  Francesca V Mertan; Liza Lindenberg; Peter L Choyke; Baris Turkbey
Journal:  Future Oncol       Date:  2016-08-16       Impact factor: 3.404

Review 6.  Stereotactic ablative body radiotherapy (SAbR) for oligometastatic cancer.

Authors:  Neil B Desai; Aaron M Laine; Robert D Timmerman
Journal:  Br J Radiol       Date:  2016-12-23       Impact factor: 3.039

7.  Patterns of treatment failure in patients with prostate cancer treated with 76-80 Gy radiotherapy to the prostate and seminal vesicles ± hormonotherapy.

Authors:  J López-Torrecilla; J Pastor-Peidro; A Vicedo-González; D González-Sanchis; A Hernandez-Machancoses; P Almendros-Blanco; E García-Miragall; J C Gordo-Partearroyo; T García-Hernández; L Brualla-González; D Granero-Cabañero; J Rosello-Ferrando
Journal:  Clin Transl Oncol       Date:  2020-07-03       Impact factor: 3.405

8.  Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease.

Authors:  William P Parker; Brian J Davis; Sean S Park; Kenneth R Olivier; Richard Choo; Mark A Nathan; Val J Lowe; Timothy J Welch; Jaden D Evans; William S Harmsen; Harras B Zaid; Ilya Sobol; Daniel M Moreira; Rimki Haloi; Matthew K Tollefson; Matthew T Gettman; Stephen A Boorjian; Lance A Mynderse; R Jeffrey Karnes; Eugene D Kwon
Journal:  Eur Urol       Date:  2016-09-03       Impact factor: 20.096

9.  Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage.

Authors:  Daniel E Spratt; Hebert A Vargas; Zachary S Zumsteg; Jennifer S Golia Pernicka; Joseph R Osborne; Xin Pei; Michael J Zelefsky
Journal:  Eur Urol       Date:  2016-08-11       Impact factor: 20.096

Review 10.  Multiparametric Magnetic Resonance Imaging of Recurrent Prostate Cancer.

Authors:  Francesca V Mertan; Matthew D Greer; Sam Borofsky; Ismail M Kabakus; Maria J Merino; Bradford J Wood; Peter A Pinto; Peter L Choyke; Baris Turkbey
Journal:  Top Magn Reson Imaging       Date:  2016-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.